EA200800879A1 - Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов - Google Patents

Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов

Info

Publication number
EA200800879A1
EA200800879A1 EA200800879A EA200800879A EA200800879A1 EA 200800879 A1 EA200800879 A1 EA 200800879A1 EA 200800879 A EA200800879 A EA 200800879A EA 200800879 A EA200800879 A EA 200800879A EA 200800879 A1 EA200800879 A1 EA 200800879A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cognitive function
ppar gamma
individual
gamma agonists
negative patients
Prior art date
Application number
EA200800879A
Other languages
English (en)
Inventor
Аллен Д. Роузес
Энн М. Сондерс
Original Assignee
ЭсБи ФАРМКО ПУЭРТО РИКО ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200800879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЭсБи ФАРМКО ПУЭРТО РИКО ИНК. filed Critical ЭсБи ФАРМКО ПУЭРТО РИКО ИНК.
Publication of EA200800879A1 publication Critical patent/EA200800879A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Способ улучшения когнитивной функции у индивида, страдающего от или восприимчивого к MCI, болезни Альцгеймера или другим деменциям, где индивид не является гомозиготным по АРОЕ4 аллелю, включающий этапы: (i) скрининг индивида для определения того, что индивид не является гомозиготным по АРОЕ4 аллелю; и затем (ii) введение указанному индивиду безопасного и эффективного количества агониста PPAR-гамма.
EA200800879A 2005-09-22 2006-09-20 Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов EA200800879A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71935305P 2005-09-22 2005-09-22
US72737705P 2005-10-17 2005-10-17
PCT/US2006/036603 WO2007038115A2 (en) 2005-09-22 2006-09-20 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients

Publications (1)

Publication Number Publication Date
EA200800879A1 true EA200800879A1 (ru) 2008-10-30

Family

ID=37876831

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200800879A EA200800879A1 (ru) 2005-09-22 2006-09-20 Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
EA200800880A EA200800880A1 (ru) 2005-09-22 2006-09-20 Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200800880A EA200800880A1 (ru) 2005-09-22 2006-09-20 Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции

Country Status (16)

Country Link
US (2) US20080226719A1 (ru)
EP (2) EP1926488A2 (ru)
JP (2) JP2009508960A (ru)
KR (2) KR20080058413A (ru)
AR (2) AR056527A1 (ru)
AU (2) AU2006295010A1 (ru)
BR (2) BRPI0616192A2 (ru)
CA (2) CA2623210A1 (ru)
CR (2) CR9849A (ru)
EA (2) EA200800879A1 (ru)
IL (2) IL190217A0 (ru)
MA (2) MA29871B1 (ru)
NO (2) NO20081843L (ru)
PE (2) PE20070618A1 (ru)
TW (2) TW200803896A (ru)
WO (2) WO2007038115A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
KR101729340B1 (ko) * 2008-08-12 2017-04-24 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
CA2766107A1 (en) * 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2012053016A1 (en) * 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
MX358594B (es) * 2011-01-10 2018-08-27 Zinfandel Pharmaceuticals Inc Factores de riesgo de enfermedad y métodos de uso.
US9102666B2 (en) 2011-01-10 2015-08-11 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating Alzheimer's disease
PE20141189A1 (es) 2011-10-21 2014-09-24 Takeda Pharmaceutical Preparacion de liberacion sostenida
CA2853100A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
JP6961694B2 (ja) * 2016-07-26 2021-11-05 オージオ・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｓ−エコールを用いてアルツハイマー病を診断するおよび治療する方法
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625212B1 (en) * 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU2192000A (en) * 1998-12-17 2000-07-03 Mindset Biopharmaceuticals (Usa) Inc. Increasing brain glucose utilization
EP1718294A4 (en) * 2004-01-30 2007-10-03 Axonyx Inc METHODS OF TREATING COMPLICATIONS OF DIABETES

Also Published As

Publication number Publication date
TW200803851A (en) 2008-01-16
WO2007038112A3 (en) 2007-12-06
CA2623210A1 (en) 2007-04-05
JP2009508959A (ja) 2009-03-05
US20080226719A1 (en) 2008-09-18
MA29872B1 (fr) 2008-10-03
KR20080056731A (ko) 2008-06-23
KR20080058413A (ko) 2008-06-25
EA200800880A1 (ru) 2009-02-27
WO2007038115A2 (en) 2007-04-05
AR056527A1 (es) 2007-10-10
PE20070618A1 (es) 2007-07-04
TW200803896A (en) 2008-01-16
AU2006295007A1 (en) 2007-04-05
BRPI0616100A2 (pt) 2011-06-07
IL190217A0 (en) 2008-11-03
WO2007038115A3 (en) 2007-12-13
IL190224A0 (en) 2008-11-03
JP2009508960A (ja) 2009-03-05
WO2007038112A2 (en) 2007-04-05
MA29871B1 (fr) 2008-10-03
NO20081843L (no) 2008-06-16
EP1940403A2 (en) 2008-07-09
US20080262047A1 (en) 2008-10-23
AR055649A1 (es) 2007-08-29
CR9848A (es) 2008-06-18
CA2623204A1 (en) 2007-04-05
BRPI0616192A2 (pt) 2011-06-14
PE20070976A1 (es) 2007-12-05
EP1926488A2 (en) 2008-06-04
AU2006295010A1 (en) 2007-04-05
NO20081847L (no) 2008-06-18
CR9849A (es) 2008-05-21

Similar Documents

Publication Publication Date Title
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
NO20052955L (no) Behandling av Huntingtons sykdom med EPA
EA200800490A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ БЕНЗО[d][1,3]ДИОКСОЛА
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
MX2007007588A (es) Analogos de tetrahidroquinolina como agonistas muscarinicos.
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
EA200401365A1 (ru) Способы лечения илеуса
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
DK1436427T3 (da) Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
UA94922C2 (ru) Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
EA200500125A1 (ru) СПОСОБ ОБОГАЩЕНИЯ И ОБНАРУЖЕНИЯ ПАТОЛОГИЧЕСКИ ИЗМЕНЕННЫХ ПРИОНПРОТЕИНОВ (PrP)
AU2003901325A0 (en) Therapeutic, prophylactic and diagnostic agents
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen